Keros Therapeutics Inc (KROS)
52.21
-1.78
(-3.30%)
USD |
NASDAQ |
May 17, 16:00
52.21
0.00 (0.00%)
After-Hours: 20:00
Keros Therapeutics Research and Development Expense (Quarterly): 38.26M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 38.26M |
| December 31, 2023 | 37.49M |
| September 30, 2023 | 34.14M |
| June 30, 2023 | 32.53M |
| March 31, 2023 | 31.09M |
| December 31, 2022 | 24.87M |
| September 30, 2022 | 21.04M |
| June 30, 2022 | 23.28M |
| March 31, 2022 | 18.08M |
| December 31, 2021 | 18.83M |
| September 30, 2021 | 14.83M |
| Date | Value |
|---|---|
| June 30, 2021 | 9.983M |
| March 31, 2021 | 11.50M |
| December 31, 2020 | 9.674M |
| September 30, 2020 | 8.395M |
| June 30, 2020 | 7.264M |
| March 31, 2020 | 8.527M |
| December 31, 2019 | 4.161M |
| September 30, 2019 | 3.854M |
| June 30, 2019 | 4.497M |
| March 31, 2019 | 4.867M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.854M
Minimum
Sep 2019
38.26M
Maximum
Mar 2024
18.11M
Average
16.46M
Median
Research and Development Expense (Quarterly) Benchmarks
| Morphic Holding Inc | 42.44M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 3.459M |